Reinvestigation of the structure-activity relationships of isoniazid.

Tuberculosis (Edinb)

Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 55455, USA. Electronic address:

Published: July 2021

AI Article Synopsis

  • Isoniazid (INH) is key for treating drug-susceptible tuberculosis, but its structure-activity relationships are not well documented.
  • Researchers tested various INH analogs against different Mycobacterium tuberculosis strains and some non-tuberculous mycobacteria, finding that certain modifications to INH structure eliminate its effectiveness.
  • The study revealed that while INH has a narrow activity spectrum and is mainly effective against mycobacteria, one analog showed some inhibitory action against a fungal strain, providing valuable insights for future research in tuberculosis treatment.

Article Abstract

Isoniazid (INH) remains a cornerstone for treatment of drug susceptible tuberculosis (TB), yet the quantitative structure-activity relationships for INH are not well documented in the literature. In this paper, we have evaluated a systematic series of INH analogs against contemporary Mycobacterium tuberculosis strains from different lineages and a few non-tuberculous mycobacteria (NTM). Deletion of the pyridyl nitrogen atom, isomerization of the pyridine nitrogen to other positions, replacement of the pyridine ring with isosteric heterocycles, and modification of the hydrazide moiety of INH abolishes antitubercular activity. Similarly, substitution of the pyridine ring at the 3-position is not tolerated while substitution at the 2-position is permitted with 2-methyl-INH 9 displaying antimycobacterial activity comparable to INH. To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of gram-positive and gram-negative bacteria, as well as a few fungi. As expected INH and its analogs display a narrow spectrum of activity and are inactive against all non-mycobacterial strains evaluated, except for 4, which has modest inhibitory activity against Cryptococcus neoformans. Our findings provide an updated analysis of the structure-activity relationship of INH that we hope will serve as useful resource for the community.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324568PMC
http://dx.doi.org/10.1016/j.tube.2021.102100DOI Listing

Publication Analysis

Top Keywords

inh analogs
12
structure-activity relationships
8
inh
8
series inh
8
pyridine ring
8
activity
5
reinvestigation structure-activity
4
relationships isoniazid
4
isoniazid isoniazid
4
isoniazid inh
4

Similar Publications

Symmetrical Bis-Hydrazone Ligand-Based Binuclear Oxido/Dioxido-Vanadium(IV/V) Complexes: Synthesis, Reactivity, and Catalytic Applications for the Synthesis of Biologically Potent 2-Phenylquinazolin-4-(3)-ones.

Inorg Chem

January 2025

Grupo NanoToxGen, Centro Interdisciplinar de Química y Biología (CICA), Departamento de Química, Facultade de Ciencias, Universidade da Coruña, A Coruna 15071, Spain.

Symmetrical bis(hydrazone)-based ligands, Hdar(bhz) (), Hdar(fah) (), Hdar(nah) (), and Hdar(inh) () obtained from 4,6-diacetylresorcinol (Hdar) and different hydrazides [benzoylhydrazide (Hbhz), isonicotinoylhydrazide (Hinh), nicotinoylhydrazide (Hnah), and 2-furoylhydrazide (Hfah)], were used to prepare potassium salts of binuclear -[VO] complexes, {K(HO)}[(VO)dar(bhz)] (), {K(HO)}[(VO)dar(fah)] (), {K(HO)}[(VO)dar(nah)] (), and {K(HO)}[(VO)dar(inh)] (), and binuclear [VO] complexes, [{VO(MeOH)}dar(bhz)] (), [{VO(MeOH)}dar(fah)] (), [{VO(MeOH)}dar(nah)] (), and [{VO(MeOH)}dar(inh)] (). In the presence of warm MeOH/DMSO (4:1), changed to {K(HO)}[(VO)Hdar(nah)]DMSO (·DMSO). Single crystal XRD studies of and confirm a binuclear structure along with a distorted square pyramidal geometry of each vanadium center where bis{ONO(2-)} ligands coordinate through phenolate-O, azomethine-N, and enolate-O atoms of each unit.

View Article and Find Full Text PDF

Serum Vitamin D Status in Infants with Cholestatic Jaundice.

Mymensingh Med J

January 2025

Dr Subir Ananda Biswas, Resident, Department of Paediatric Gastroenterology & Nutrition, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail:

Cholestatic jaundice is a potentially serious condition that requires early diagnosis for proper management. Fat-soluble vitamin (FSV) deficiency develops as a consequence of cholestasis. Vitamin D deficiency is common and remains a challenge in patients with cholestasis.

View Article and Find Full Text PDF

Isoniazid and rifampicin co-therapy are the main causes of anti-tuberculosis drug-induced liver injury (ATB-DILI) and acute liver failure, seriously threatening human health. However, its pathophysiology is not fully elucidated. Growing evidences have shown that fibroblast growth factors (FGFs) play a critical role in diverse aspects of liver pathophysiology.

View Article and Find Full Text PDF

Membrane interaction studies of isoniazid derivatives active against drug-resistant tuberculosis.

Eur J Pharm Sci

February 2025

Departamento de Química e Bioquímica, Faculdade de Ciências, Centro de Química Estrutural, Institute of Molecular Sciences, Universidade de Lisboa, Campo Grande 1749-016, Portugal. Electronic address:

Tuberculosis is one of the leading causes of mortality worldwide due to the growth of multi-drug resistant strains unsusceptible to currently available therapies. Four compounds, isoniazid (INH) and three derivatives, N'-decanoylisonicotinohydrazide (INHC10), N'-(E)-(4-phenoxybenzylidene)isonicotinohydrazide (N34) and N'-(4-phenoxybenzyl)isonicotinohydrazide (N34red), were studied. Owing to their advantageous in vitro selectivity index against the primary mutation responsible for drug resistance in Mycobacterium tuberculosis (Mtb), as well as their suitable lipophilicity and interaction with human serum albumin, INHC10 and N34 were deemed promising antitubercular compounds.

View Article and Find Full Text PDF

Hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH) is a rare disorder characterized by recurrent, potentially life-threatening swelling in various parts of the body, including the limbs, face, and airways Current treatments focus primarily on symptomatic relief and the management of acute attacks, without targeting the underlying genetic cause or the dysregulated bradykinin production. Donidalorsen, a novel antisense oligonucleotide, addresses a key driver of HAE-C1-INH by targeting prekallikrein (PKK) to reduce bradykinin levels. This meta-analysis evaluates the efficacy and safety of Donidalorsen versus placebo, focusing on two dosing regimens: 4-week and 8-week intervals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!